These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33193410)

  • 1. Measurement of Human Papillomavirus-Specific Antibodies Using a Pseudovirion-Based ELISA Method.
    Toh ZQ; He L; Chen C; Huang A; Russell FM; Garland SM; Reyburn R; Ratu T; Tuivaga E; Frazer IH; Mulholland EK; Licciardi PV
    Front Immunol; 2020; 11():585768. PubMed ID: 33193410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination.
    Zhao H; Lin ZJ; Huang SJ; Li J; Liu XH; Guo M; Zhang J; Xia NS; Pan HR; Wu T; Li CG
    Hum Vaccin Immunother; 2014; 10(3):740-6. PubMed ID: 24384608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a human papillomavirus (HPV) multiplex immunoassay to profile HPV antibodies.
    Quang C; Chung AW; Kemp TJ; Ratu T; Tuivaga E; Russell FM; Licciardi PV; Toh ZQ
    J Med Virol; 2024 Jun; 96(6):e29732. PubMed ID: 38874202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
    Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S
    Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.
    Brown D; Müller M; Sehr P; Pawlita M; Seitz H; Rubio I; Antonello J; Radley D; Roberts C; Saah A
    Vaccine; 2014 Oct; 32(44):5880-7. PubMed ID: 25148777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
    Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
    PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine.
    Dessy FJ; Giannini SL; Bougelet CA; Kemp TJ; David MP; Poncelet SM; Pinto LA; Wettendorff MA
    Hum Vaccin; 2008; 4(6):425-34. PubMed ID: 18948732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial.
    Krajden M; Cook D; Yu A; Chow R; Mei W; McNeil S; Money D; Dionne M; Karunakaran KP; Palefsky JM; Dobson S; Ogilvie G; Petric M
    Clin Vaccine Immunol; 2011 Mar; 18(3):418-23. PubMed ID: 21248158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity correlation in cynomolgus monkeys between Luminex-based total IgG immunoassay and pseudovirion-based neutralization assay for a 14-valent recombinant human papillomavirus vaccine.
    Bei L; Zhang X; Meng D; Gao S; Jia J; Zhao D; Luo C; Li X; Qiu H; Xie L
    J Med Virol; 2022 Aug; 94(8):3946-3955. PubMed ID: 35388509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.
    Brown DR; Garland SM; Ferris DG; Joura E; Steben M; James M; Radley D; Vuocolo S; Garner EI; Haupt RM; Bryan JT
    Hum Vaccin; 2011 Feb; 7(2):230-8. PubMed ID: 21307649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplex immunoassay to measure antibody response to nine HPV vaccine types.
    Panicker G; Rajbhandari I; Pathak HN; Brady AM; Unger ER
    J Immunol Methods; 2021 Nov; 498():113136. PubMed ID: 34464605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unveiling the seroprevalence of human papillomavirus in Guangdong, China: Implications for vaccination strategies.
    Hu X; Chen Y; Lin W; Ruan Q; Chen H; Li X; Deng Y; Liang C; Lin H; Zeng L; Sun N; Zhao W; Chen L; Yang Y; Sun L; He J; Sun J
    J Med Virol; 2024 Sep; 96(9):e29910. PubMed ID: 39228341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection.
    Longet S; Schiller JT; Bobst M; Jichlinski P; Nardelli-Haefliger D
    J Virol; 2011 Dec; 85(24):13253-9. PubMed ID: 21976653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.
    Roberts C; Green T; Hess E; Matys K; Brown MJ; Haupt RM; Luxembourg A; Vuocolo S; Saah A; Antonello J
    Hum Vaccin Immunother; 2014; 10(8):2168-74. PubMed ID: 25424920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
    Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
    Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.
    Wentzensen N; Rodriguez AC; Viscidi R; Herrero R; Hildesheim A; Ghosh A; Morales J; Wacholder S; Guillen D; Alfaro M; Safaeian M; Burk RD; Schiffman M
    J Infect Dis; 2011 Jul; 204(1):94-102. PubMed ID: 21628663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Lebacq M; van der Most R; Moris P; Giannini SL; Schuind A; Datta SK; Descamps D;
    Hum Vaccin; 2011 Dec; 7(12):1359-73. PubMed ID: 22048172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of a triple-color pseudovirion-based neutralization assay for immunogenicity assessment of a 14-valent recombinant human papillomavirus vaccine.
    Gao S; Zhao D; Feng C; Kou Y; Lu J; Luo C; Li X; Wang Y; Xie L
    J Med Virol; 2024 Aug; 96(8):e29859. PubMed ID: 39145587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses.
    Sehr P; Rubio I; Seitz H; Putzker K; Ribeiro-Müller L; Pawlita M; Müller M
    PLoS One; 2013; 8(10):e75677. PubMed ID: 24124504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.